Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
Intensity Therapeutics (INTS) Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shares of Intensity Therapeutics, Inc. (INTS) are up 142% on Friday after the company announced positive Phase 2 INVINCIBLE trial data of INT230-6 in patients with early-stage breast cancer without chemotherapy.
By Chris Wack Intensity Therapeutics shares doubled to $9.09 after the company said it saw positive data from its Phase 2 trial of INT230-6 in patients with.
Intensity Therapeutics said Friday efficacy data from its phase 2 trial of INT230-6 in people with early-stage breast cancer showed a high order of necrosis in presurgical breast cancer tumors in.